Literature DB >> 21333494

Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis.

Hsin-Yi Yang1, Ya-Hui Tzeng, Chiah-Yang Chai, An-Tsz Hsieh, Jiun-Rong Chen, Le-Shin Chang, Sien-Sing Yang.   

Abstract

OBJECTIVE: Non-alcoholic steatohepatitis (NASH) is a common cause of liver disease, and it may progress to fibrosis or cirrhosis. The aim of this study was to investigate the effects of soy protein on hepatic steatosis and insulin resistance in NASH.
METHODS: Forty male Sprague-Dawley rats were fed a high-fat diet for 4 wk to induce NASH and then were allocated to one of four diets: a NASH-inducing diet, a standard diet, a NASH-inducing diet plus soy protein, and a standard diet plus soy protein.
RESULTS: After the 10-wk experimental period, the results showed that soy protein significantly lowered plasma cholesterol concentrations and body fat accumulation. Soy protein intake also decreased the hepatic lipid depots of triacylglycerols and cholesterol and decreased the concentrations of lipid peroxides. In an analysis of antioxidative status, rats fed the soy protein diet showed improved antioxidative potential due to increases in superoxide dismutase and catalase activities and a decrease in the protein expression of cytochrome P450 2E1.
CONCLUSION: Soy protein may improve the liver function in patients with NASH by lowering lipid levels in the blood and liver, increasing the antioxidative capacity, and improving insulin resistance.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21333494     DOI: 10.1016/j.nut.2010.09.004

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  22 in total

Review 1.  Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.

Authors:  Long-Xin Qiu; Tong Chen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance.

Authors:  Tawfik Khoury; Ami Ben Ya'acov; Yehudit Shabat; Lidya Zolotarovya; Ram Snir; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

3.  Raspberry ketone protects rats fed high-fat diets against nonalcoholic steatohepatitis.

Authors:  Lili Wang; Xianjun Meng; Fengqing Zhang
Journal:  J Med Food       Date:  2012-05       Impact factor: 2.786

4.  The α' subunit of β-conglycinin and various glycinin subunits of soy are not required to modulate hepatic lipid metabolism in rats.

Authors:  Cynthia Chatterjee; Jiajie Liu; Carla Wood; Christine Gagnon; Elroy R Cober; Judith A Frégeau-Reid; Stephen Gleddie; Chao-Wu Xiao
Journal:  Eur J Nutr       Date:  2017-03-21       Impact factor: 5.614

5.  Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats.

Authors:  Matthew R Panasevich; Colin M Schuster; Kathryn E Phillips; Grace M Meers; Sree V Chintapalli; Umesh D Wankhade; Kartik Shankar; Dustie N Butteiger; Elaine S Krul; John P Thyfault; R Scott Rector
Journal:  J Nutr Biochem       Date:  2017-05-31       Impact factor: 6.048

Review 6.  Medicinal Plants and Phytochemicals Regulating Insulin Resistance and Glucose Homeostasis in Type 2 Diabetic Patients: A Clinical Review.

Authors:  Atena Mahdavi; Mohammad Bagherniya; Mohammad Sadegh Mirenayat; Stephen L Atkin; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development.

Authors:  Jian-Ping Liu; Wen-Li Zou; Shui-Jiao Chen; Hong-Yun Wei; Ya-Ni Yin; Yi-You Zou; Fang-Gen Lu
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

8.  Isoflavones-Enriched Soy Protein Prevents CCL(4)-Induced Hepatotoxicity in Rats.

Authors:  Nesma A Z Sarhan; Ezzeldein S El-Denshary; Nabila S Hassan; Ferial M Abu-Salem; Mosaad A Abdel-Wahhab
Journal:  ISRN Pharmacol       Date:  2012-03-01

Review 9.  4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics.

Authors:  Francesca Maria Trovato; Daniela Catalano; Giuseppe Musumeci; Guglielmo M Trovato
Journal:  EPMA J       Date:  2014-12-07       Impact factor: 6.543

Review 10.  Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents.

Authors:  Ali Hashemi Kani; Seyed Moayed Alavian; Fahimeh Haghighatdoost; Leila Azadbakht
Journal:  Hepat Mon       Date:  2014-02-17       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.